Applicants reserve their rights to file divisional application directed to the cancelled subject matter. Claims 23 to 25 have also been amended to clarify the present invention. Applicants submit that no new matter has been added via the amendment to the specification. Claims 23 to 26 are pending.

The examiner has pointed out several informalities. Applicants submit that some of these informalities have been addressed. Claims 27 and 28 have been cancelled as being drawn to a non-elected invention. The specification has been amended to insert the status of the present application. While the drawings have been objected to under 37 C.F.R. 1.84, Applicants will respond to this objection upon allowance of this application.

Claims 23-26 have been objected to for alleged lack of clarity. Therefore, Claims 23-25 have been amended to conform with the examiner's suggestion. Therefore, this objection should be rendered moot.

Claims 23-25 have been rejected under 35 U.S.C. § 101 since the claimed invention was directed to non-statutory subject matter. In order to obviate the rejection, the claims have been amended to recite "An isolated peptide or polypeptide", thereby rendering this rejection moot.

Claims 23-26 have been rejected under 35 U.S.C. § 112, first paragraph, because there was no Declaration of availability concerning the microorganisms. Enclosed please find an executed Declaration of availability. Therefore, this rejection is rendered moot.

Claim 23 has been rejected under 35 U.S.C. § 112, first paragraph, allegedly because it was not clear to the examiner, from the results of Table 1, which amino acid sequence the monoclonal antibody, 64G12, is reacting with. For the following reasons, this rejection is respectfully traversed.

In Example 1 (page 14), the application discloses the construction of a plasmid for the expression in E. coli of the extracellular domain (amino acid 27 to 427) of the human IFN-R (figure 2). It is clearly specified that this plasmid was introduced in the E. coli strain, JM 105.

At least on page 16, the construction of another expression vector coding for the IFN-R amino acid sequence 1-427, with an additional 5-histidyl residues at the C-terminus, is disclosed. This second plasmid was introduced into Cos7 cells.

Therefore, the E. coli cells mentioned in Table 1 express the IFN-R 27-427 fragment, whereas the Cos cells in the same table express the IFN-R 1-427 fragment.

Hence, it is clear from the results shown in Table 1 that the monoclonal antibody, 64G12, is reacting with both the 27-427 and 1-427 fragments.

Thus, in view of the above, withdrawal of this rejection is respectfully requested.

Claims 24 and 25 have been rejected under 35 U.S.C. § 112, first paragraph, allegedly because there was no evidence of record that peptides or polypeptides consisting of the amino acid sequence 27-229 or 1-229 of SEQ ID No: 1 or 2 would bind specifically to the monoclonal antibody, 64G12. Enclosed please find a Declaration under 37 C.F.R. § 1.132, by Michael G. Tovey, where the fact that these peptides or polypeptides bind specifically to the monoclonal antibody, 64G12, is illustrated.

Therefore, in view of the above, withdrawal of this rejection is respectfully requested.

Claims 23-26 have been rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains or with which it is nearly connected, to make and/or use the invention. However, for the following reasons, this rejection is respectfully traversed.

The instant claims recite "a portion" of a peptide or polypeptide consisting of the amino acid sequences 27-427, 27-229 or 1-229 of SEQ ID No: 1 or 2, or an analogue of the amino acid sequence 27-427, each binding specifically to the monoclonal antibody, 64G12. The examiner asserts that the specification "is not enabled for such "a portion" of any of the amino acid sequence recited, and for their binding specificity with the monoclonal antibody, 64G12." See Office Action mailed September 3, 1999, page 6, last sentence. The examiner says that there is no evidence that such "a portion" consisting, for example, of two amino acid residues would bind specifically to the monoclonal antibody, 64G12.

It is respectfully submitted that it is obvious to one skilled in the art that a polypeptide must be longer than merely two amino acids to be recognized by an antibody. Taking into account the fact that the monoclonal antibody, 64G12, is available, Applicants respectfully submit that enough specific guidance is provided in the specification and the examples to permit a person skilled in the art at the time of the effective filing date of the instant application to reproducibly practice the invention as claimed. Indeed, the artisan skilled in the art only had to produce a set of overlapping peptides and test their binding to 64G12, as explained, for example, in the enclosed Declaration. This kind of experiment is classically used in the field of the invention, for the mapping of epitopes. It is therefore known by the skilled artisan.

The necessary experiments are merely routine, and thus are not undue experimentation, as explained in *Ex porte Jackson* 217, USPQ 804 (Bd. Pat. App. 1982):

> "The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed to enable the determination of how to practice a desired embodiment of the invention claimed . . ."

Therefore, in view of the above, withdrawal of this rejection is respectfully requested.

Claim 26 has been rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains or with which it is nearly connected, to make and/or use the invention. However, for the following reasons, this rejection is respectfully traversed.

The instant claims recite an "analogue" of a peptide or polypeptide consisting of the amino acid sequences 27-427 of SEQ ID No: 1 or 2, which retains the ability to bind specifically to the monoclonal antibody, 64G12. The examiner asserts that the specification is not enabled for such an "analogue" of the amino acid sequence recited and for their binding specificity with the monoclonal antibody, 64G12. The examiner says that there is no evidence that such an "analogue" would bind specifically to the monoclonal antibody, 64G12.

It is respectfully submitted that it is obvious to one skilled in the art that peptides or polypeptides such as those claimed in the present application comprise a particular epitope(s) that is recognized by the antibody, and that other parts of the molecule can be substituted without changing the binding affinity of said peptides or polypeptides with the antibody. Taking into account the fact that the monoclonal antibody, 64G12, is available, Applicants respectfully submit that enough specific guidance is provided in the specification and the examples to permit a person skilled in the art at the time of the effective filing date of the instant application to reproducibly practice the invention as claimed. Indeed, the skilled artisan only had to produce the desired mutant and to test its binding to the monoclonal antibody, 64G12.

The necessary experiments are merely routine, and thus are not undue experimentation, as explained in above-cited *Ex parte Jackson* (1982).

Therefore, in view of the above, withdrawal of this rejection is respectfully requested.

Claims 23-26 have been rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for falling to particularly point out and distinctly claim the subject matter which Applicants regard as the invention.

For the following reasons, this rejection is respectfully traversed.

The peptides or polypeptides claimed in Claims 23-20 are characterized by the two following characteristics:

(1) they are derived from (i.e., identical to, a portion of, or an analogue of) the extracellular portion of the IFN-R of SEQ ID NO: 2,

(2) they specifically bind to monoclonal antibody 64G12.

A peptide or polypeptide of the invention must have both of these elements. The presence of these elements is very simple to test, the first point being checked by sequencing and the second point by contacting said peptide or polypeptide with said monoclonal antibody, 64G12, and evaluating their binding.

Therefore, it is respectfully submitted that the scope of Claims 23-26 is clear enough to a person skilled in the art, and withdrawal of this rejection is hence requested.

Applicants wish to note that the examiner has not indicated his consideration of the prior art references submitted on August 2, 1999. Applicants request that examiner return

an appropriately initialed 1449 form. A copy of the submitted 1449 form is enclosed, along with a copy of the acknowledged receipt.

Applicants soon will forward copies the submitted declarations to replace the facsimile versions enclosed herein.

In view of the foregoing amendments and remarks it is believed that the application now is in condition for allowance. A favorable disposition of the application therefore is solicited. The examiner also is invited to contact the undersigned if there are any questions or if the examiner believes that further discussion will advance prosecution.

Respectfully submitted,

35,087

March 3, 2000
Date

Bernhard D. Saxe
Registration No. 28,665

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
(202) 672-5300

PATENT

Attorney Docket No. 017283/0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BENOIT et al.

Serial No.: 09/240,675

Filed: 02/02/99

For: MONOCLONAL ANTIBODY AGAINST ALPHA IFN

Group Art Unit: 1641

Examiner: DEVI, S

Declaration pursuant to 37 C.F.R. § 1.132

Hon. Commissioner of Patents
and Trademarks

Washington, D.C. 20231

I, Michael G. TOVEY, do hereby declare and state the following :

1. That I have received a Special Bachelor of Sciences in Microbiology in 1969 and a Ph.D. in Microbiology in 1972 from the University of London. I am currently Director of the Laboratory of Viral Oncology (UPR CNRS 9046) in Villejuif, France. I am or have been a member of the Editorial Boards of several reviews including the Journal of Interferon Research, Oncology Reports, and Cellular Pharmacology. I am also a member of the Scientific Boards of several organisations, particularly in the fields of Oncology and Immunogenetics. Enclosed, please find a copy of my *curriculum vitae*, which clearly indicates my expertise in the fields of Oncology and Immunogenetics.

2. I am one of the inventors of the above-captioned patent application and therefore I am very familiar with the subject application. I have read and understood the latest Official Action issued by the U.S. Patent and Trademark Office on September 3, 1999. It is my understanding that Claims 24 and 25 were rejected under 35 U.S.C. § 112, first paragraph, as not being reasonably enabled. In rendering this rejection, it appears that the Examiner deems that no evidence is of record that peptides or polypeptides consisting of the amino acid sequences 1-229 or 27-229 of SEQ ID NO: 1 or 2 would bind specifically to the monoclonal antibody, 64G12.

3. In order to address the issue of enablement concerning the subject-matter of Claims 24 and 25, the following experiments, were conducted under my supervision. A brief explanation of why these experiments were conducted and the results of these experiments are set forth below :

Interfons (IFNs) in common with other cytokines activate Janus tyrosine kinases and latent STAT transcription factors upon binding to their cell surface receptor. Type I IFNs bind to a receptor composed of two transmembrane polypeptides, IFNAR1 and IFNAR2, which belong to the class II cytokine receptor family that also includes the cellular receptors for IFN-γ, Interleukin-10 and coagulation protease factor VII (Tissue factor). The extracellular domain of the Type I IFN receptor chain IFNAR1, has four fibronectin type-III sub-domains. Human IFNAR1 has intrinsic weak affinity for Type I IFNs and plays an essential role in transmembrane signaling, formation of a high affinity complex with IFN and the modulation of ligand specificity.

4. Reactivity of the 64G12 mAb against various bovine/human IFNAR1 chimeras

Human IFNAR1 is a cell surface glycoprotein, composed of a large extracellular region (457 amino acids), a single transmembrane domain (21 amino acids) and a cytoplasmic domain (100 amino acids). The extracellular region is divided into 4 subdomains separated by conserved di- or tri-proline motifs denoted SD1 to SD4. Although 66% of the amino acids are conserved between bovine and human IFNAR1, the 64G12 mAb does not recognize bovine IFNAR1. Bovine/human IFNAR1 chimeras, produced in transiently transfected COS cells, have proved to be a useful tool for mapping different mAbs agains IFNAR1 subdomains (Goldman et al., 1998, 37: 13003-13010). Thus, the cell surface reactivity of fluorescent labelled 64G12 mAb was assayed by flow cytometry against 8 different bovine/human chimeras encompassing the 4 subdomains (SD1 to SD4, see Table I). The results of these experiments clearly show, that the presence of the human SD1 (residues 28-123) subdomain, is an absolute requirement for the binding of the 64G12 mAb to the hybrid chimeras.

HHHH	+	BBBB	-
HBHH	+	BHBB	-
HHBH	+	BBHB	-
HHHB	+	BBBH	-
HBBB	+	BHHH	-

Table 1: Reactivity of the 64G12 mAb against various bovine/human IFNAR1 chimeras expressed transiently at high levels in COS cells.

The chimeras (H for human and B for bovine), represent the 4 extracellular subdomains (SD1-4), starting at the amino terminus (SD1: residues 28-123, SD2: residues 124-232, SD3: residues 233-335, SD4: residues 336-436)

5. IFNAR1-derived overlapping peptide scans for the mapping of the linear 64G12 epitope

The 64G12 mAb inhibits binding of the Type I IFNs to [illegible] transmembrane complex IFNAR1-IFNAR2 and competes specifically with IFN-α [illegible] for cell surface receptor binding. Although the antibody is able to remove IFN bound to its cell surface receptor, IFN cannot remove the bound antibody. Thus, in order to [illegible] determine the precise role of putative IFNAR1 target amino acids in IFN binding, epitope mapping of the site recognized by the monoclonal antibody 64G12 was performed.

In order to characterize the ligand binding site on IFNAR1, the epitope recognized by the IFN-α and IFN-β was analyzed. The target peptide recognized by the 64G12 mAb was determined by screening a set of 48 overlapping peptides covering the first two subdomains (residues 23-229) of the extracellular region of IFNAR1. The results of this study show that the peptide (FSSLKLNVY), localized within the first sub-domain, exposed thereafter, (residues 89-97) of IFNAR1 is recognized by the 64G12 mAb.

Mapping of the 64G12 linear epitope was carried out using IFNAR1-derived scans of overlapping 20-mer biotinylated peptides, prepared by solid phase synthesis, as a tool for probing the SD1 and SD2 domains (residues : 23-229) of the human IFNAR1 ectodomain (Table 2). We chose biotinylated peptides as they exhibit a low level of non specific binding when detecting sequential epitopes. A number of observations suggested that a sequential epitope was present. Thus, the 64G12 mAb is able to recognize completely denatured IFNAR1 in lysates from a variety of different cell lines using Western blotting or immunoprecipitation. Similar results are obtained using deglycosylated recombinant IFNAR1 or whole transmembrane IFNAR1 from cell extracts. In addition, 64G12 was able to recognize native or denatured recombinant IFNAR1 produced in E. coli. A copy of an article (Eid and Tovey, 1995/J. Interferon Res./15: 205-211) is enclosed, which reports that the 64G12 antibody is directed against the first two subdomains SD1 and SD2 (amino acids 1-[illegible]9), of IFNAR1. The most relevant passages are indicated (abstract and page 208).

The ELISA screening of the 48 biotinylated IFNAR1 peptides was performed on streptavidin-coated plates as described in the experimental procedures. The data, presented in Figure 2, indicate that the epitope recognized by the 64G12 mAb is located in the first subdomain (SD1) of the extracellular moiety of IFNAR1. Specific binding of the 64G12 mAb to the coated peptides was observed in the region corresponding to peptides 14-15. No specific binding was seen when an irrelevant mouse IgG1 was used to screen the streptavidin linked peptides (Figure 1, Table 2).

11
SHOULD BE FIGURE 1
MBT.
02-03-00.



FIGURE 1. **Binding of anti-IFNAR1 mAb (64G12) to overlapping peptides coated-plates.** The monoclonal antibody 64G12 mAb was scanned in ELISA with a set of overlapping biotinylated 20 mer peptides, each offset by four residues, spanning the SD1, and SD2 subdomains (residues 23-237, Table 1) of the human IFNAR1 molecule. Peptides are numbered from 1 to 48 starting from the N-terminus. Histograms represent the binding of 64G12 for each coated peptide and the continuous line, the binding of an irrelevant mouse IgG1. The data presented are the average of two independent experiments. Values are the means of duplicate determinations.



Fig 4

Peptide	Position	Sequence	M.W	pI	Binding %
1	23-42	AARGGKNLKSPQKVEVDIID	2052.6	6.34	30
2	27-46	GKNLKSPQKVEVDIIDDNFI	2271.8	4.49	33
3	31-50	KSPQKVEVDIIDDNFILRWH	2428.9	4.48	34
4	35-54	KVEVDIIDDNFILRWHRSDE	2475.9	4.03	35
5	39-58	DIIDDNFILRWHRSDESVGN	2377.8	3.79	28
6	43-62	DNFILRWHRSDESVGNVTFS	2355.7	4.36	32
7	47-66	LRWHRSDESVGNVTFSFDYQ	2413.7	6.36	30
8	51-70	RSDESVGNVTFSFDYQKTGM	2367.6	4.36	27
9	55-74	SVGNVTFSFDYQKTGMDSWI	2308.7	3.92	29
10	59-78	VTFSFDYQKTGMDSWIKLSG	2336.8	6.07	43
11	63-82	FDYQKTGMDSWIKLSGCQNI	2361.8	6.03	35
12	67-86	KTGMDSWIKLSGCQNITSTK	2224.9	9.05	39
13	71-90	DSWIKLSGCQNITSTKCNFS	2258.9	8.00	46
14	75-94	KLSGCQNITSTKCNFSSLKL	2172.8	9.19	62
15	79-98	CQNITSTKCNFSSLKLNYYE	2291.9	7.93	93
16	83-102	TSTKCNFSSLKLNYYEIKLR	2317.0	8.20	100
17	87-106	CNFSSLKLNYYEIKLRIRA	2396.2	9.06	77
18	91-110	SLKLNYYEIKLRIRAEKEN	2445.1	8.68	64
19	95-114	NYYEIKLRIRAEKENTSSW	2464.9	6.50	41
20	99-118	IKLRIRAEKENTSSWYEVD	2465.9	4.93	34
21	103-122	IRAEKENTSSWYEVDSFTP	2414.7	4.78	30
22	107-126	KENTSSWYEVDSFTPFRKA	2420.7	4.78	50
23	111-130	SSWYEVDSFTPFRKAQIGP	2315.7	6.26	41
24	115-134	EVDSFTPFRKAQIGPPEVH	2316.7	5.55	29
25	119-138	FTPFRKAQIGPPEVHLEAE	2252.7	5.61	28
26	123-142	RKAQIGPPEVHLEAEDKAI	2247.8	5.63	28
27	127-146	IGPPEVHLEAEDKAIVIHI	2207.8	4.75	30
28	131-150	EVHLEAEDKAIVIHISPGT	2154.7	4.75	27
29	135-154	EAEDKAIVIHISPGTKDSV	2121.7	4.63	31
30	139-158	KAIVIHISPGTKDSVMWAL	2180.9	7.15	28
31	143-162	IHISPGTKDSVMWALDGLS	2135.8	5.23	28
32	147-166	PGTKDSVMWALDGLSFTYS	2161.7	3.92	33
33	151-170	DSVMWALDGLSFTYSLLIW	2345.1	3.92	31
34	155-174	WALDGLSFTYSLLIWKNSS	2332.1	5.95	30
35	159-178	GLSFTYSLLIWKNSSGVEE	2244.8	3.96	44
36	163-182	TYSLLIWKNSSGVEERIEN	2384.9	4.71	26
37	167-186	LIWKNSSGVEERIENIYSR	2406.0	6.45	39
38	171-190	NSSGVEERIENIYSRHKIY	2422.0	8.70	31
39	175-194	VEERIENIYSRHKIYKLSP	2431.1	8.70	33
40	179-198	IENIYSRHKIYKLSPTTTY	2511.2	9.47	37
41	183-202	YSRHKIYKLSPTTTYCLKV	2442.3	9.42	54
42	187-206	KIYKLSPTTTYCLKVKAAL	2306.2	9.41	37
43	191-210	LSPTTTYCLKVKAALLTSW	2262.0	8.99	47
44	195-214	TTTYCLKVKAALLTSWKIG	2224.0	8.99	46
45	199-218	CLKVKAALLTSWKIGVYSP	2176.0	9.60	65
46	203-222	KAALLTSWKIGVYSPVRCI	2214.1	9.60	33
47	207-226	LTSWKIGVYSPVRCIKTTV	2260.9	8.22	28
48	210-229	WKIGVYSPVRCIKTTVENL	2315.9	7.98	29

Table 2 : Sequences and analytical data of overlapping human biotinylated synthetic peptides derived from the human IFNAR1 receptor protein. Peptides are numbered according to the position of the amino-terminal residue within the IFNAR1 sequence. Sequences corresponding to the epitope peptide are underlined. Binding % represents the 64G12 binding to coated peptides relative to maximum binding. Results are the means of two independent experiments.

	Peptide Sequence	MW	pI	Binding Score
1	NFSSL	565.7	5.5	48
2	NFSSLK	693.9	9.01	41
3	NFSSLKL	807.1	9.01	43
4	NFSSLKLN	921.2	9.01	55
5	NFSSLKLNV	1020.3	9.01	52
6	NFSSLKLNVY	1183.5	8.85	100
7	KLNVYE	763.9	6.21	57
8	LKLNVYE	877.1	6.21	50
9	SLKLNVYE	964.2	6.21	61
10	SSLKLNVYE	1051.3	6.21	73
11	FSSLKLNVYE	1198.5	6.21	96
12	NFSSLKLNVYE	1312.6	6.21	98
13	NFSSLK[redacted]NVYE	1270.5	6.21	43
14	NFSSLK[redacted]NVYE	1256.5	6.21	47
15	NFSSL[redacted]LNVYE	1255.5	3.75	42
16	NFSSL[redacted]LNVYE	1241.5	3.75	44
17	NFSS[redacted]KLNVYE	1270.5	6.21	73
18	NFSS[redacted]KLNVYE	1256.5	6.21	65
19	NFS[redacted]LKLNVYE	1296.6	6.21	98
20	NFS[redacted]LKLNVYE	1282.6	6.21	82
21	NO PEPTIDE	-	-	38

Table 3

6. **Contribution of individual residues of the IFNAR1-epitope to the binding of the 64G12 mAb**

Analysis of the peptide sequence interacting with the 64G12 mAb, revealed a common sequence (NFSSLKLNVYE), mapping to residues 88-98 of the IFNAR1 SD1 domain. In order to determine the smallest peptide required for antibody binding, and the relative importance of each constituent amino acid involved in binding, a series of 20 chimeric biotinylated peptides were synthesized in which a single residue only was modified or deleted from one peptide to another. The following conclusions can be drawn from data presented in Table 3 and Figure 4 as to the relative importance in antibody binding of each individual residue of the sequence :

Beginning with the full sequence (NFSSLKLNVYE), the deletion of either the amino-terminal N or the carboxyl terminal E has little or no effect on antibody binding. The further deletions from the amino terminus of F decreases specific binding by about 50%, while the combined deletion of F and S further decreases binding. Any further deletion from the amino terminus lowers binding to approximately background levels. From the carboxyl terminus, the deletion of the Y reduces antibody binding to near background levels ; further deletions from this end are equivalent to the tyrosine deletion and, therefore, are uninformative. Thus, the minimum full-binding peptide is the 8-mer, FSSLKLNVY (residues 89-97). Within this sequence, the binding of 64G12 is slightly sensitive to the substitution of glycine (but not alanine) at the second serine, and is more sensitive to alanine and glycine at the first leucine. However, the K or second L appear critical for antibody binding, since their substitution by alanine or glycine decreases antibody binding to background levels. Thus, positions throughout the nonapeptide have varying effects on binding to 64G12.

7. As a conclusion, the above results clearly demonstrate that peptides or polypeptides consisting of the amino acid sequences 1-229 or 27-229 of SEQ ID NO: 1 or 2 specifically bind to the monoclonal antibody, 64G12.

8. I further declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

2-03-00.

Date

Michael G. TOVEY

PATENT

Attorney Docket No. 017283/0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
BENOIT et al.

Group Art Unit: 1641

Serial No.: 09/240,979

Examiner: DEVI, S.

Filed: February 2, 1999

For: MONOCLONAL ANTIBODIES AGAINST ALPHA IFN

DECLARATION OF AVAILABILITY

ASSISTANT COMMISSIONER FOR PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

SIR:

The undersigned, a representative of MEDISUP INTERNATIONAL N.V., having a place of business at Kaya W.F.G. Mensing 14, 431 Netherlands Antilles, declares and states that:

1. I have reviewed the Assignment in the above-identified application, a copy of which is attached hereto, and I believe in good faith that MEDISUP INTERNATIONAL N.V. is the Assignee of the entire right, title and interest in and to the invention described and claimed in application Serial No. 09/240,875, filed September 3, 1999, for MONOCLONAL ANTIBODIES AGAINST THE INTERFERON RECEPTOR, WITH NEUTRALIZING ACTIVITY AGAINST TYPE I INTERFERON.

2. Cell culture 64G12 was deposited at the ECACC, PHLS CAMR, PORTON DOWN on 25th February, 1992, under accession No. 92022805.

3. Access to the culture will be available during pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. 1.14 and 35 U.S.C. 122.

4. All restrictions on the availability to the public of the culture so deposited will be irrevocably removed upon the granting of the patent.

5. MEDISUP INTERNATIONAL N.V. will maintain the deposited culture, and will refurnish such culture should it become non-viable while on deposit.

6. The deposited culture will be maintained at said depositary for a period of at least five years after the most recent request for the furnishing of a sample of the deposited cultures was received by the depositary, and, in any case, for a period of at least thirty (30) years after the date of the deposit, or during the enforceable life of the patent, whichever is later.

I further state that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such will full false statements may jeopardize the validity of the application or any patent issuing thereon.

March 2nd, 2000
Date

Signature

Kevin MARTIN.
Typewritten Name

Managing Director.
Official Title

CURRICULUM VITAE

Michael G. TOVEY

PRESENT AFFILIATION

Director of the Laboratory of Viral Oncology (UPR CNRS 9045) C.N.R.S.
Institut de Recherches sur le Cancer,
FR Y1221- 7 rue Guy Môquet - BP 8
94801 Villejuif Cedex, France
Tel. (33-1) 49 58 34 23/49 58 34 34.
Fax (33-1) 49 58 34 44

PERSONAL

Birth :	March 8, 1945
Citizenship :	British

EDUCATION

B.s.C. 1969	Special Microbiology, London University
Ph.D. 1972	Microbiology, London University

RESEARCH AND ACADEMIC APPOINTMENTS

Sept. 1968 - Oct. 1971	Assistant (Department of Microbiology - Prof. S. Pirt) Queen's Elizabeth College, London.
1969 - 1971	Assistant in Biochemistry, Queen's Elizabeth College, London.
	Assistant in Bacteriophage genetics and animal virology, Queen's Elizabeth College, London.
1971 - April 1973	Post-doctoral research fellow of European Molecular Biology Organization at the Institut de Recherches Scientifiques sur le Cancer, Laboratory of Viral Oncology (Dr Ion Gresser), Villejuif, France.
April 1973 - Dec. 1976	Attaché de recherche I.N.S.E.R.M. at the Institut de Recherches Scientifiques sur le Cancer, Villejuif, France.
Dec.1976 - Dec. 1979	Chargé de Recherche I.N.S.E.R.M. at the Institut de Recherches Scientifiques sur le Cancer, Villejuif, France.
Jan.1980 - 1983	Maître de Recherche I.N.S.E.R.M. at the Institut de Recherches Scientifiques sur le Cancer, Villejuif, France.

Jan. 1984 - 1997	Directeur de Recherche 2 I.N.S.E.R.M. at the Institut de Recherches Scientifiques sur le Cancer, Villejuif, France.
Jan. 1998	Directeur de Recherche 1 I.N.S.E.R.M. at the Institut de Recherches Scientifiques sur le Cancer, Villejuif, France.
Jan. 1984	Fogarty visiting Professor, Rockefeller University, New York, U.S.A.
1987-1991	Member of the Molecular Biology Commission of INSERM Member of the Steering Committee of INSERM Molecular Biology Commission
1988-1992	Member of the Scientific Board of Faculty of Medicine, University Paris XI
1989	Founded the European Biotechnology Corporation
Since 1990	Member of the Scientific Board of INSERM Unit 268
January 1995	Director of the Laboratory of Viral Oncology, UPR CNRS 9045 at the Institut de Recherches sur le Cancer - IFC1, Villejuif, France

MEMBERSHIP OF EDITORIAL BOARDS AND SCIENTIFIC COMMITTEES

- Member of the Editorial Board of the Journal of Interferon Research
- Member of the Editorial Board of Oncology Reports
- Member of the Editorial Board of Cellular Pharmacology
- Member of the Publication Committee of the International Society for Interferon and Cytokine Research
- Vice-President of the Scientific Board of the Prix Européen de l'Avenir
- Vice-President of the Association of the Institut of Cancer and Immunogenetics, Villejuif, France
- Member of the Scientific Board of the Institut of Cancer and Immunogenetics, Villejuif, France
- General Secretary of the Association for Biomedical Research (ANRB)
- Member of the Scientific Board of the International Center for AIDS Research in Africa (CILSA)
- Member of the Scientific Board of Medinvest, Compagnie Financière Edmond de Rothschild

PUBLICATIONS

1. Mogensen K.E., Tovey M.G., Mathison G.E. and Pirt S.J.
Induction of mouse interferon in a chemically defined system.
J. gen. Virol., 16 : 111-114, 1972.

2. Tovey M.G., Mathison G.E. and Pirt S.J.
The production of interferon by chemostat cultures of mouse LS-cells grown in chemically-defined, protein-free medium.
J. gen. Virol., 20 : 29-35, 1973.

3. Frayssinet C., Tovey M.G., Gresser I. and Lindahl P.
Inhibitory effect of potent interferon preparations of the regeneration of mouse liver after partial hepatectomy.
Nature, 245 : 146-147, 1973.

4. Gresser I., Bandu M-T., Tovey M.G., Bodo G., Paucker K. and Stewart II W.E.
Inhibitory effect of highly purified interferon preparations on the multiplication of leukemia L1210 cells.
Proc. Soc. Exp. Biol. Med., 142 : 7-10, 1973.

5. Tovey M.G., Begon-Lours J. and Gresser I.
A method for the large scale production of potent interferon preparations.
Proc. Soc. Exp. Biol. Med., 146 : 809-815, 1974.

6. Gresser I., Bandu M-T., Brouty-Boyé D. and Tovey M.G.
Pronounced antiviral activity of human interferon on bovine and porcine cells.
Nature, 251 : 543-545, 1974.

7. Tovey M.G., Brouty-Boyé D. and Gresser I.
Early effect of interferon on mouse leukemia cells cultivated in a chemostat.
Proc. Natl. Acad. Sci. USA, 72 : 2265-2269, 1975.

8. Gresser I., Tovey M.G. and Bourali-Maury C.
Efficacy of exogenous interferon treatment initiated after onset of multiplication of vesicular stomatitis virus in the brains of mice.
J. gen. Virol., 27 : 222-233, 1975.

9. Gresser I., Tovey M.G., Maury C. and Chouroulinkov I.
Lethality of interferon preparations for new-born mice.
Nature, 258 : 76-78, 1975.

10. Tovey M.G. and Brouty-Boyé D.
Characteristics of the chemostat culture of murine leukemia L1210 cells.
Exp. Cell Res., 101 : 346-354, 1976.

11. Tovey M.G. and Brouty-Boyé D.
The cultivation of animal cells in a chemostat.
J. App. Chem. & Biotech., 26 : 345, 1976.

12. Gresser I., Tovey M.G., Bandu M-T., Maury C. and Brouty-Boyé D.
Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection.
J. Exp. Med., 144 : 1305-1315, 1976.

13. Gresser I., Tovey M.G., Maury C. and Bandu M-T.
Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease and influenza virus.
J. Exp. Med., 144 : 1316-1323, 1976.

14. Gresser I., Maury C. and Tovey M.G.
Interferon and murine leukemia VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in AKR mice.
Int. J. Cancer, 17 : 647-651, 1976.

15. Stewart II, W.E., Gresser I., Tovey M.G., Bandu M-T. and Le Goff S.
Identification of the cell-multiplication-inhibitory factors in interferon preparations as interferons.
Nature, 262 : 300-302, 1976.

16. Lindahl P., Gresser I., Leary P. and Tovey M.G.
Interferon treatment of mice : enhanced expression of histocompatibility antigens on lymphoid cells.
Proc. Natl. Acad. Sci. USA, 73 : 1284-1287, 1976.

17. Gresser I., Morel-Maroger L., Maury C., Tovey M.G. and Pontillon F.
Progressive glomerulonephritis in mice treated with interferon preparations at birth.
Nature, 263 : 420-422, 1976.

18. Lindahl P., Gresser I., Leary P. and Tovey M.G.
Enhanced expression of histocompatibility antigens of lymphoid cells in mice treated with interferon.
J. Inf. Dis., supplement 133 : A66-A68, 1976.

19. Tovey M.G., Begon-Lours J., Gresser I. and Morris A.G.
Marked enhancement of interferon production in 5-bromodeoxyuridine treated human lymphoblastoid cells.
Nature, 267 : 455-457, 1977.

20. Tovey M.G., Bandu M-T., Begon-Lours J., Brouty-Boyé D. and Gresser I.
Antiviral activity of bovine interferons on primate cells.
J. gen. Virol., 36 : 341-344, 1977.

21. Brouty-Boyé D. and Tovey M.G.
Inhibition of thymidine uptake in chemostat cultures of L1210 cells.
Intervirology, 9 : 243-252, 1978

22. Gresser I., Maury C. and Tovey M.G.
Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice.
Eur. J. Cancer, 14 : 97-99, 1978.

23. Gresser I., Maury C., Bandu M-T., Tovey M.G. and Mannoury M-T.
Role of endogenous interferon in the antitumor effect of poly I.C, and statolon as demonstrated by the use of anti-mouse interferon serum.
Int. J. Cancer, 21 : 72-77, 1978.

24. Rivière Y., Gresser I., Guillon J-C. and Tovey M.G.
Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice.
Proc. Natl. Acad. Sci. USA, 74 : 2135-2138,1978.

25. De Maeyer-Guignard J., Tovey M.G., Gresser I. and De Maeyer E.
Purification of mouse interferon by sequential affinity chromatography on poly(U) and antibody-agarose columns.
Nature, 271 : 622-625, 1978.

26. Gresser, I. and Tovey, M.G.
Antitumor effects of interferon.
Biochem. Biophys. Acta, 516 : 231-247, 1978.

27. Tovey M.G., Lenoir G. and Begon-Lours J.
Activation of latent Epstein-Barr virus by antibody to human IgM.
Nature, 276 : 270-272, 1978.

28. Gresser I., Tovey M.G., Maury C. and Bandu M-T.
Role of interferon in the pathogenesis of herpes simplex virus disease in mice.
In: Oncogenesis and Herpes Viruses, vol. 3 (eds. De Thé G., Henle W. & Rapp F.) (Int. Agency Res. Cancer, Lyon) pp. 1049-1054, 1979.

29. Tovey M.G. and Brouty-Boyé D.
The use of the chemostat to study the relationship between cell growth rate, viability and the effect of interferon on L1210 cells.
Exp. Cell Res., 118 : 383-388, 1979.

30. Gresser I., Morel-Maroger L., Châtelet F., Maury C., Tovey M.G., Bandu M-T., Buywid J. and Delanche M.
Delay in growth and the development of nephritis in rats treated with interferon preparations in the neonatal period.
Am. J. Pathol., 95 : 329-346, 1979.

31. Tovey M.G., Lenoir G., Begon-Lours J., Tapiero H. and Rochette-Egly C.
The effect of mitogens on the expression of Epstein-Barr virus antigens in human lymphoid cell lines.
J. Immunol., 123 : 138-142, 1979.

32. Tovey M.G., Rochette-Egly C. and Castagna M.
Effect of interferon on concentrations of cyclic nucleotides in cultured cells.
Proc. Natl. Acad. Sci. USA, 76 : 3890-3893, 1979.

33. Gresser I., De Maeyer-Guignard J., Tovey M.G. and De Maeyer E.
Electrophoretically pure mouse interferon exerts multiple biologic effects.
Proc. Natl. Acad. Sci. USA, 76 : 5308-5312, 1979.

34. Gresser I., Morel-Maroger L., Rivière Y., Guillon J-C., Tovey M.G., Woodrow D., Sloper J.C. and Moss J.
Interferon induced disease in mice and rats.
Annals New York Acad. Sci., 350 : 12-20, 1980.

35. Tovey M.G. and Rochette-Egly C.
The effect of interferon on cyclic nucleotides.
Annuals New York Acad. Sci., 350 : 266-278, 1980.

36. Lenoir G., Tovey M.G. and Lavoué M-F.
Induction of Epstein-Barr virus early antigen by phytohaemagglutinin in the presence of 5-iodo-2'-deoxyuridine : application to EBV serology.
J. Immunol. Methods, 34 : 23-29, 1980.

37. Tovey M.G., Rochette-Egly C. and Castagna M.
Correlation between growth rate, cell density, and intracellular concentrations of cyclic nucleotides in chemostat cultures of mouse L1210 cells.
J. Cell Physiol., 105 : 363-367, 1980.

38. Tovey M.G.
The cultivation of animal cells in the chemostat : application to the study of tumor cell multiplication.
In: Advances in Cancer Research, 33 : 1-37, 1980.

39. Adam C., Thoua Y., Ronco P., Verroust P., Tovey M.G. and Morel-Maroger L.
The effect of exogenous interferon : acceleration of autoimmune and renal diseases in (NZB/W)F1 mice.
Clin. Exp. Immunol., 40 : 373-382, 1980.

40. Tovey M.G.
Viral latency and its importance in human disease.
Path. Biol. 26 : 631-634, 1980.

41. Gresser I., Morel-Maroger L., Rivière Y., Guillon J-C., Tovey M.G. and Woodrow D.
Interferon-induced disease in mice and rats.
In: Communications of liver cells. Falk Symposium 27 - MTP Press Ltd. (H. Hopper et al., eds) 1980.

42. De Maeyer-Guignard J., De Maeyer E., Tovey M.G. and Gresser I.
Electrophoretically pure mouse interferon exerts multiple biological effects.
Annuals New York Acad. Sci., 350 : 347-353, 1980.

43. Tovey M.G.
Use of the chemostat culture for study of the effect of interferon on tumor cell multiplication.
In : Methods in Enzymology, vol. 79 : Interferons Part B (S. Pestka, ed.) Academic Press, New York, pp. 391-404, 1981.

44. Tovey M.G. and Rochette-Egly C.
Rapid increase in guanosine 3'5'-monophosphate in interferon treated cells.
In: The Biology of the Interferon System (E. De Maeyer and H. Schellekens, eds.), Elsevier/North Holland, pp. 165-168, 1981.

45. Tovey M.G. and Rochette-Egly C.
Rapid increase in guanosine 3'5'-monophosphate in interferon treated mouse leukemia L1210 cells : relationship to the development of the antiviral state and inhibition of cell multiplication.
Virology, 115 : 272-281, 1981.

46. Tovey M.G., Dron M. and Gresser I.
Interferon enhances the expression of Epstein-Barr virus early antigen in Daudi cells.
J. gen. Virol., 60 : 31-38, 1982.

47. Yerushalmi A., Tovey M.G. and Gresser I.
Antitumor effect of combined interferon and hyperthermia in mice.
Proc. Soc. Exp. Biol. Med., 169 : 413-415, 1982.

48. Kawade Y., Aguet M. and Tovey M.G.
Antigenic correlations between components of C243 and L cell interferons.
Antiviral Res., 2 : 155-159, 1982.

49. Keller R., Aguet M., Tovey M.G. and Stitz L.
Prevention of interferon-induced augmentation of cellular antitumor effector mechanisms by phorbol esters.
Cancer Res., 42 : 1468-1472, 1982.

50. Tovey M.G., Gresser I., Rochette-Egly C., Begon-Lours-Guymarho J., Bandu M-T., Maury C.
Indomethacin and aspirin do not inhibit the antiviral and anti-proliferative action of interferon.
J. gen. Virol., 63 : 505-508, 1982.

51. Tovey M.G. and Gresser I.
Interferon-induced disease in mice and rats.
In: The Clinical Potentials of Interferons in Viral Diseases and Malignant Tumors. (R. Kono and J. Vilcek, eds.) University of Tokyo Press, pp. 311-319, 1982.

52. Tovey M.G.
Interferon and cyclic nucleotides.
In: Interferon 4, 1982 (I. Gresser, ed.) Academic Press, London-New York, pp. 23-46.

53. Tovey M.G., Rochette-Egly C. and Kolb J-P.
Interferon enhancement of natural killer cell cytotoxicity : role of cyclic nucleotides.
J. Interferon Res., 2 : 549-561, 1982.

54. Rochette-Egly C. and Tovey M.G.
Interferon enhances guanylate cyclase activity in human lymphoma cells.
Biochem. Biophys. Res. Commun., 107 : 150-156,1982.

55. Rosa F., Fellous M., Dron M., Tovey M.G. and Revel M.
Presence of an abnormal β2-microglobulin in mRNA in Daudi cells : induction by interferon.
Immunogenetics, 17 : 125-131, 1983.

56. Tovey M.G., Vincent C., Gresser I. and Revel M.
The effect of DNA methylation on the expression of human interferon α genes.
In: The Biology of the Interferon System. Proceedings of the International Meeting on the Biology of the Interferon System, Rotterdam. (Eds. E. De Maeyer, G. Galasso and H. Schellekens)Elsevier/North Holland, pp. 45-50, 1983.

57. Hoshino A., Takenaka H., Mizukoshi O., Imanishi J., Kishida T. and Tovey M.G.
Effect of anti-interferon serum of influenza virus infection in mice.
Antiviral Res., 3 : 59-65, 1983.

58. Tovey M.G.
The cultivation of animal cells in continuous-flow culture.
In: Animal Cell Biotechnology (eds R.E. Spier and B. Griffiths) Academic Press, New York, vol.1, pp. 195-210, 1985.

59. Dron M. and Tovey M.G.
Isolation of Daudi cells with reduced sensitivity to interferon. I. Characterization.
J. gen. Virol., 64 : 2641-2647, 1983.

60. Tovey M.G., Dron M., Mogensen K.E., Leblen B., Mechti N., and Bégon-Lours-Guymarho J.
Isolation of Daudi cells with reduced sensitivity to interferon. II. On the mechanisms of resistance.
J. gen. Virol., 64 : 2649-2653,1983.

61. Gresser I., Belardelli F., Maury C., Maunoury M-T. and Tovey M.G.
Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors.
J. Exp. Med., 158 : 2095-2107, 1983.

62. Tovey M.G.
Interferon : immunomodulator and antitumor agent.
In: Immunomodulation. (ed. H. Hugh Fudenberg, H.D. Whitten and F. Ambrogi) Plenum Publishing Corporation, pp. 155-159, 1984.

63. Sonyri-Caporale M., Tovey M.G., Ono K., Jasmin C. and Chermann J-C.
Modulation by the polyoxotungstate HPA-23 of early antigen expression in Raji cells treated with iododeoxyuridine.
J. gen. Virol., 65 : 831-835, 1984.

64. Rochette-Egly M. and Tovey M.G.
Natural killer cell cytotoxicity : role of calmodulin.
Biochem. Biophys. Res. Commun., 121 : 478-486, 1984.

65. Tovey M.G. and Gresser I.
Interferon induced disease.
In: "The Physiology and Pathology of Interferon System (ed. L. Borecky and V. Lackovic). Contr. Oncol., vol. 20, pp. 196-204, Karger, Basel, 1984.

66. Pozzetto B., Mogensen K.E., Tovey M.G. and Gresser I.
Characterization of auto-antibodies to human interferon in a patient with a varicella zoster.
J. Infect. Dis., 105 : 707-713, 1984.

67. Gresser I., Belardelli F., Vignaux F., Maury C., and Tovey M.G.
Role of endogenous "spontaneous" interferon in mice.
In: "The Biology of the Interferon System, 1984", Heidelberg. H. Kirchner and H. Schellekens (eds.). Elsevier Science Publishers B.V., Amsterdam, The Netherlands, p. 16, 1984.

68. Dron M. and Tovey M.G.
Interferon resistant Daudi cells : on the mechanisms of resistance.
In: "The Biology of the Interferon System, 1984", Heidelberg. H. Kirchner and H. Schellekens (eds.). Elsevier Science Publishers B.V., Amsterdam, The Netherlands, p. 40, 1984.

69. Rochette-Egly C. and Tovey M.G.
Cyclic GMP levels in interferon treated cells.
Antiviral Res., 5 : 127-135, 1985.

70. Gresser I., Vignaux F., Belardelli F., Tovey M.G. and Maunoury M-T.
Injection of mice with antibody to mouse interferon α/β decreases the level of 2'-5'oligo-adenylate synthetase in peritoneal macrophages.
J. Virol., 53 : 221-227, 1985.

71. Dron M., Tovey M.G. and Eid P.
Interferon induced proteins : relationship to the phenotype of interferon resistance in cloned Daudi cells.
J. gen. Virol., 66 : 785-795, 1985.

72. Gresser I., Belardelli F., Vignaux F. and Tovey M.G.
Is interferon produced constitutively in normal mice ?
In: The Interferon System. (Eds. F. Dianzani and G.B. Rossi), vol. 24, pp. 99-102, Raven Press, New York, 1985.

73. Le Rosconet D., Vodjdani G., Lemaigre-Dubreuil Y., Tovey M.G., Latta M. and Doly J.
Structure of a murine alpha interferon pseudogene with a repetitive R-type sequence in the 3' flanking region.
Mol. Cell. Biol., 5 : 1343-1348, 1985.

74. Tovey M.G. and Gresser I.
Detection of interferon messenger RNA in the organs of normal mice.
In: The Interferon System. (Eds. F. Dianzani and G.B. Rossi), vol. 24, pp. 109-113, Raven Press, New York, 1985.

75. Gresser I., Belardelli F., Vignaux F., Maury C. and Tovey M.G.
Role of endogenous "spontaneous" interferon in mice.
In: The Biology of the Interferon System. (Eds. H. Kirchner and H. Schellekens), pp. 157-160, Elsevier Publishers, B.V., Amsterdam, The Netherlands, 1986.

76. Dron M., Tovey M.G. and Uzé G.
Isolation of Daudi cells with reduced sensitivity to interferon. IV. Characterization of clones with altered binding of human interferon subspecies.
J. gen. Virol., 67 : 663-669, 1986.

77. Dron M., Modjtahedi N., Brison O. and Tovey M.G.
Interferon modulation of c-myc expression in cloned Daudi cells : relationship to the phenotype of interferon resistance.
Mol. Cell. Biol., 6 : 1374-1378, 1986.

78. Gresser I., Belardelli F., Maury C., Tovey M.G. and Maunoury M-T.
Antitumor effects of interferon in mice injected with interferon-resistant Friend leukemia cells. IV. Definition of optimal treatment regimens.
Int. J. Cancer, 38 : 251-257, 1986.

79. Meister A., Uzé G., Mogensen K.E., Gresser I., Tovey M.G., Grütter M. and Meyer F.
Biologic activities and receptor binding of 2 human recombinant interferons and their hybrids.
J. gen. Virol., 67 : 1633-1643, 1986.

80. Tovey M.G., Streuli M., Gresser I., Gugenheim J., Blanchard B., Guymarho J., Vignaux F. and Gigon M.
Interferon messenger RNA is produced constitutively in the organs of normal individuals.
Proc. Natl. Acad. Sci. USA, 84 : 5038-5042, 1987.

81. Tovey M.G., Gresser,I.
Interferon β-2 is expressed at high levels in the organs of normal individuals.
J. Interferon Res. (Abstract), 7 : 701, 1987.

82. Palmieri M., Tovey M.G.
Evidence for the presence of regulatory proteins in the 5'untranslated region of the interferon α-1 gene in cells from normal individuals.
J. Interferon Res. (Abstract), 7 : 711, 1987.

83. Besançon F., Silbermann F., Dron M., Tovey M.G., Thang M.N., and Bourgeade M-F.
Relationship between inhibition of cell growth and of transferrin receptor expression by interferon (IFN) α : Studies in IFN-sensitive and IFN-resistant Daudi cells.
J. gen. Virol., 68 : 2647-2654, 1987.

84. Tovey M.G., and Gresser I.
Interferon as an antiviral agent : role of endogenous interferon.
In : Development in Antiviral Chemotherapy (ed. M. Alexander). Ecomed Landsberg, 1987.

85. Tovey M.G.
The expression of cytokines in the organs of normal individuals : role in homeostasis.
J. of Biol. Reg. & Homeost. Agents, 2 : 87-92, 1988.

86. Tovey M.G., Content J., Gresser I., Gugenheim J., Blanchard, B., Poupart, P., Gigou, M., Shaw, A., and Fiers, W.
Genes for interferon β-2 (interleukin-6), tumor necrosis factor, and interleukin-1 are expressed at high levels in the organs of normal individuals.
J. Immunology, 141 : 3106-3110, 1988.

87. Gresser, I., Maury, C., Vignaux, F., Haller, O., Belardelli, F. and Tovey, M.G.
Antibody to mouse interferon α/β abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice.
J. Exp. Med., 168 : 1271-1291, 1988.

88. Tovey, M.G. and Palmieri, M.
Expression of interferon and cytokine genes in normal individuals and in patients with auto-immune diseases. The 1988 ISIR meeting on Interferon and Cytokines, Kyoto 14-18, 1988.
J. of Interferon Res. 8 suppl.1 : S156, 1988.

89. Dron, M., Tovey, M.G., Maury, C., Eid, P., Meyer, F. and Gresser, I.
Production and in vivo biologic actions of recombinant mouse interferon α2.
J. Biol. Regul. & Homeost. Agents, 3 : 13-19, 1989.

90. Tovey, M.G.
Expression of the genes of interferons and other cytokines in normal and diseased tissues of man.
Experientia, 45 : 526-535, 1989.

91. Tovey, M.G., Gresser, I., Blanchard, B. and Guymarho, J.
Expression of IL-6 in normal individuals and in patients with autoimmune disease.
In "Regulation of the acute phase and immune responses: Interleukin-6.
Ann. N.Y. Acad., 557 : 363-373, 1989.

92. Tovey, M.G., and Palmieri, M.
Expression of interferon and cytokine genes in normal individuals and in patients with autoimmune diseases.
In "The Biology of the Interferon System 1988". Kawade, Y., and Kobayashi, eds., pp. 329-334, 1989.

93. Dron, M., Lacasa, M., Tovey, M.G.
Priming affects the activity of a specific region of the promoter of the human beta IFN gene.
Mol. & Cell. Biol., 10 : 854-858, 1990.

94. Palmieri, M., and Tovey, M.G.
Genomic footprinting: Detection of putative regulatory proteins in the promoter region of the interferon α-1 gene in normal human tissues.
Mol. & Cell. Biol., 10 : 2554-2561, 1990.

95. Vanden Broecke, C., Caillat-Zucman, S., Legendre, C., Noël, L-H., Kreis, H., Woodrow, D., Bach, J-F., and Tovey, M.G.
Differential in situ expression of cytokines in renal allograft rejection.
Transplantation, 51 : 602-609, 1991.

96. Caillat-Zucman, S., Vanden Broecke, C., Legendre, C., Noel, L-H., Kreis, H., Bach, J-F., and Tovey, M.G.
Differential in situ expression of cytokine genes in human renal rejection.
Transplantation Proceedings, 23/1 : 229-231, 1991.

97. Vanden Broecke, C., and Tovey, M.G.
The expression of the genes of class I interferons and interleukin 6 in individual cells.
J. Interferon Res., 11 : 91-1031991.

98. Vanden Broecke, C., Caillat-Zucman, S., Legendre, C., Noel, L-H., Kreis, H., Bach, J.-F., Tovey, M.G.
Study of graft rejection using molecular biology technics.
In : "Immunologic, metabolic, and infectious aspects of hepatic transplantation", ed. D.A. Vuitton, John Libbey LTD, London, 1991.

99. Tovey, M.G.
The antiproliferative action of interferons.
Seminars in Oncology, W.B. Saunders Company, 1991.

100. Tovey, M.G., Gugenheim, J., Guymarho, J., Blanchard, B., Vanden Broecke, C., Gresser, I., Bismuth, H., and Reynes, M.
Genes for interleukin-1, interleukin-6, and tumor necrosis factor are expressed at markedly reduced levels in the livers of patients with severe liver disease.
Autoimmunity, 10 /4: 297-310, 1991.

101. Proietti, E., Vanden Broecke, C., Di Marzio, P., Gessani, S., Gresser, I., and Tovey, M.G.
Specific interferon genes are expressed in individual cells in the peritoneum and bone marrow of normal mice.
J. Interferon Res., 12 : 27-34, 1992.

102. Dron, M., and Tovey, M.G.
Interferon α/β gene structure and regulation.
In : Interferon: Principles and Medical Applications, (eds. S. Baron *et al.*), 33-45, 1992.

103. Dron, M., Rebouillat, D., and Tovey, M.G.
Tandem repeat polymers of a critical region of the human interferon β promoter exhibit a marked constitutive activity and enhanced responsiveness to transcriptional regulators in transfected HeLa cells.
J. Interferon Res., 12 : 377-384, 1992.

104. Tovey, M.G., Lebon, P., Rizza, P., and Lallemand, C.
The expression of interferon genes in the tissues of AIDS-patients.
In : The IFN-system in HIV-infection", VII European Interferon Workshop, 26-28 February, 1992, Hanover.

105. Tovey, M.G., Lebon, P., Meyer, F., Hurtrel, B., Gresser, I., Venet, A., and Girard, M.
The role of interferon in the development of AIDS:
"1992 Annual Meeting of the International Society for Interferon Research" September 28-October 2, 1992, Toronto.

106. Lallemand, C., and Tovey, M.G.
Differential expression of IFN genes in cells infected with HIV.
"1992 Annual Meeting of the International Society for Interferon Research" September 28-October 2, 1992, Toronto.

107. Krivine, A., Tovey, M.G., Taty-Taty, R., and Lebon, P.
Endogenous interferon alpha in newborns from HIV seropositive mothers.
"1992 Annual Meeting of the International Society for Interferon Research" September 28-October 2, 1992, Toronto.

108. Tovey, M.G., Lebon, P., Meyer, F., Hurtrel, B., Gresser, I., Venet, A., Girard, M., and Aubertin, A.-M.
The role of interferon in the development of AIDS.
"Tenth Annual Symposium on Nonhuman Primate Models for AIDS", San Juan, Puerto Rico, 14-22 November, 1992.

109. Gugenheim, J., Tovey, M.G., Gigou, M., Crafa, F., Fabiani, B., Reynes, M., Bismuth, H.
Prolongation of hert allograft survival in rats by anti-interferon antibodies and low-dose cyclosporine.
Transplant. International, 1992.

110. Benoit, P., Maguire, D., Plavec, I., Kocher, H-P., Tovey, M.G., and Meyer, F.
A monoclonal antibody to recombinant human IFN α receptor inhibits biological activity of several species of human IFN α, IFN β and IFN ω.
J. Immunol., 150 : 707-716, 1993.

111. Tovey, M.G., Doglise-Favre, A., and Schoevaert, D.
Differential in situ expression of cytokine genes in human renal transplantation.
Kidney International, 43 : 129, 1993.

112. Dron, M. and Tovey, M.G.
Interferon-resistant Daudi cells are deficient in interferon α-induced ISGF3 α production, but remain sensitive to the interferon α-induced increase in ISGF3 γ content.
J. Interferon Res., 13 : 377-383, 1993.

113. Tovey, M.G.
Le Patrimoine immatériel et intellectuel : Le séquençage du génome humain.
Actes du Forum d'Iéna, 1 : 76-78, 1993.

114. Tovey, M.G., Lebon, P., Meyer, F., Hurtrel, B., Gresser, I., Venet, A., Girard, M., Aubertin, A.M.
Antibody to the human IFN α receptor reduces the loss of CD4+ T cells in macaques infected with the simian immunodeficiency virus (SIV).
J. Interferon Res. 13 (suppl. 1) : S202, 1993.

115. Tovey, M.G.
Differences between IFN-α and IFN-β both from the point of view of gene regulation and physico-chemical properties etc.
In : Proceedings of 1993 International Symposium on Viral Hepatitis and Liver Diseases.
Medical Tribune, Inc.,1994.

116. Militerno, G., Gugenheim, J., Cuomo, O., Hofman, P., Moniel, J., Tovey, M.G.
Synergistic interaction between anti-IFN α/β antibody and low doses of cyclosporin therapy prolongs heart transplants in rats.
Transplantation Proc., 26 : 3050-3051, 1994.

117. Tovey, M.G., Lebon, P., Eid, P., Meyer, F., Hurtrel, B., Gresser, I., Venet, A., Girard, M. and Aubertin, A-M.
Antibody to the human IFN α receptor reduces the loss of CD4+ T cells in macaques infected with the simian immunodeficiency virus (SIV).
BioTech RIA '94 Congress. Florence, April 11-13, 1994.

118. Lallemand, C., Rizza, P., Lebon, P. and Tovey, M.G.
Mechanisms of the inhibition of the interferon response in HIV infected cells.
BioTech RIA '94 Congress, Florence, April 11-13, 1994.

119. Tovey, M.G., Benizri, E., Gugenheim, J., Bernard, G., Eid, P., Hofman, P.
An interferon alpha antagonist induces permanent allograft survival in cynomologus monkeys. (Abs)
J. Interferon Res., 14 : S168, 1994.

120. Lallemand, C., Rizza, P., Lebon, P., Tovey, M.G.
Constitutive expression of specific type I interferons in peripheral blood leukocytes from normal individuals and in the promonocytic cell line U937.(Abs.)
J. Interferon Res., 14 : S62, 1994.

121. Abramovich, C., Shulman, L.M., Ratovitski, E., Harroch, S., Tovey, M.G., Eid, P., and Revel, M.
Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to interferon-α and interferon-β
EMBO J., 13 : 5871-5877, 1994.

122. Eid, P. and Tovey, M.G.
Characterization of a domain of a human type I interferon receptor protein involved in ligand binding.
J. Interferon Res., 15 : 205-211, 1995.

123. Gresser, I., Maury, C., Kaido, T., Bandu, M-T., Tovey, M.G., Maunoury, M-T., Fantuzzi, L., Gessani, S., Greco, G., Proietti, E., and Belardelli, F.
The essential role of endogenous IFN α/β in the antimetastatic action of sensitized T lymphocytes in mice injected with Friend erythroleukemia cells.
Int. J. Cancer, 63 : 726-731, 1995.

124. Tovey, M.G., Benizri, E., Gugenheim, J., Bernard, G., Eid, P., Blanchard, B., and Hofman, P.
Role of the type I interferons in allograft rejection.
J. Leukocyte Biol., 59 : 512-517, 1996.

125. Weill, D., Gay, F., Tovey, M.G., and Chouaib, S.
Induction of tumor necrosis factor-α expression in human T lymphocytes following ionizing gamma irradiation.
J. Interferon & Cytokine Res., 16 : 395-402, 1996.

126. Khatissian, E., Tovey, M.G., Cumont, M-C., Monceaux, V., Lebon, P., Montagnier, L., Hurtrel, B., and Chakrabarti, L.
Rapid interferon-alpha response does not prevent the establishment of a high viral burden in primary SIV infection.
AIDS Res. & Human Retroviruses, in press, 1996.

127. Merola, M., Blanchard, B., and Tovey, M.G.
The κB enhancer of the human interleukin-6 promoter is the unique IL-1β and TNF α responsive element/requirement for members of the C/EBP family for activity.
J. Interferon & Cytokine Res., 16 : 783-798, 1996.

128. Lallemand, C., Lebon, P., Rizza, P., Blanchard, B., and Tovey, M.G.
Constitutive expression of specific interferon isotypes in peripheral blood leukocytes from normal individuals and in promonocytic U937 cells.
J. Leukocyte Biol., 60 : 137-146, 1996.

129. Cursio, R., Gugenheim, J., Tovey, M., Lasfar, A., Crafa, F., Michiels, J.-F., and Mouiel, J.
Protective properties of anti-IFN α/β antibodies in normothermic hepatic ischaemia in the rat.
Transplantation Proc., 28 : 73-74, 1996.

130. Lang, M-C., Cansier, C., Rizza, P., Jasmin, C., Tovey, M.G., and Eid, P.
A comparative study of the expression of cellular proteins in uninfected and HIV infected U937 cells using two dimensional SDS polyacrylamide gel electrophoresis.
Chemico-Biological Interactions, 103 : 179-186, 1997.

131. Lallemand, C., Bayat-Sarmadi, M., Blanchard, B., and Tovey, M.G.
Identification of a novel transcriptional regulatory element common to the P53 and IRF1 genes.
The J. Biol. Chemistry, 272/47 : 29801-29809, 1997.

132. Benizri, E., Gugenheim, J., Lasfar, A., Eid, P., Blanchard, B., Lallemand, C., and Tovey, M.G.
Prolongation allograft survival in cynomologus monkeys treated with a monoclonal antibody human type I interferon receptor and low doses of cyclosporin A.
J. Interferon & Cytokine Res., 18 : 273-284, 1998.

133. Dandoy-Dron, F., Guillo, F., Benboudjema, L., Deslys, J-Ph., Lasmezas, C., Dormont, D., Tovey, M.G., and Dron, M.
Gene expression in scrapie : cloning of a new scrapie responsive gene and the identification of increased levels of seven other mRNA transcripts.
J. Biol. Chem., 273 : 7691-7697, 1998.

134. Dron, M., Dandoy-Dron, F., Guillo, F., Benboudjema, L., Knuw, J.-J., Lebon, P., Dormont, ., and Tovey, M.G.
Characterization of the human analogue of a Scrapie responsive gene.
J. Biol. Chem., 273 : 18015-18018, 1998.

135. Armenante, F., Merola, M., Furia, A., Tovey, M.G., and Palmieri, M.
IL-6 gene transcription is associated with chromatin remodeling of the promoter and is independent of nuclear factor loading.
J. Biol. Chem., sous presse, .

136. Dron, M., Hameau, L., Benboudjema, L., Guymarho, J., Cajean-Feroldi, C., Rizza, P., Godard, C., Tovey, M.G., Jasmin, C., and Lang, M.-C.
Cloning of a long HIV-1 readthrough transcript and detection of an increased level of Egr-1 mRNA in chronically infected U937.
Arch. Virol., 144 : 19-28, 1999.

137. Eid, P., Méritet, J.-F., Maury, C., Lasfar, A., Weill, D. and Tovey, M.G.
Oromucosal interferon therapy : Pharmacokinetics and pharmacodynamics.
J. Interferon & Cytokine Res., 19 : 157-169, 1999.

138. Tovey, M.G. and Maury, C.
Oromucosal interferon therapy : Marked antiviral and antitumor activity.
J. Interferon & Cytokine Res., 19 : 145-155, 1999.

139. Tovey, M.G., Méritet, J-F., Guymarho, J. and Maury, C.
Mucosal cytokine therapy: Marked antiviral and antitumor activity.
J. Interferon & Cytokine Res., 19 : 911-921, 1999.

140. Palmieri, M., Sasso, M.P., Monese, R., Merola, M., Faggioli, L., Tovey, M., and Furia, A.
Interaction of the nuclear protein CBF1 with the kB site of the IL-6 gene promoter.
Nucleic Acids Res. 27 : 2785-2791, 1999.

141. Dandoy-Dron, F., Benboudjema, L., Guillo, F., Jaegly, A., Jasmin, C., Dormont, D., Tovey, M.G., and Dron, M.
Enhanced levels of scrapie responsive gene mRNA in BSE-infected mouse brain.
Mol. Brain Res., in press, 2000.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 15:205–211 (1995)
Mary Ann Liebert, Inc., Publishers

Characterization of a Domain of a Human Type I Interferon Receptor Protein Involved in Ligand Binding

PIERRE EID and MICHAEL G. TOVEY

ABSTRACT

Two monoclonal antibodies that recognize different epitopes of the extracellular domain of one of the proteins that constitute the type I interferon receptor were used to delineate the interferon binding site. Antibody 64G12 both inhibits the binding of radiolabeled interferon-α_2 and IFN-α_8 to their cell surface receptors and neutralizes the antiviral and antiproliferative actions of all the type I interferons tested, including IFN-β, IFN-ω, and human leukocyte IFN, a mixture of different interferon-α isotypes. Antibody 34F10 recognizes the type I interferon receptor with an affinity similar to that of the MAb 64G12 but does not inhibit either the binding or the biologic activity of any of the type I interferons tested. Both antibodies recognize a protein of 105 ± 5 kD from either Daudi or Ly28 cells. Immunoprecipitation following surface iodination demonstrated that the neutralizing MAb recognizes a protein of 105 kD and the nonneutralizing MAb a protein of 110 kD in extracts of Daudi cells. A second less intense band was also detected by both antibodies. Cross-linking of IFN-α_2 to its receptor before immunoprecipitation prevented the neutralizing antibody from immunoprecipitating the receptor protein, but the nonneutralizing MAb was still able to recognize a 140 kD protein corresponding to the cross-linked interferon-receptor protein complex. Thus, an interferon binding domain appears to be localized in a region between amino acids 23 and 229 of the extracellular domain of a transmembrane protein that forms part of the type I interferon receptor complex containing the epitopes recognized by each antibody.

INTRODUCTION

THE INTERFERONS (IFN) are multifunctional cytokines that comprise proteins of three antigenic classes, α, β, and γ. The α interferons are encoded by a superfamily of 14 functional α genes and a single functional ω gene.[1–3] The β and γ interferons are encoded by single copy genes. Interferons exert their characteristic biologic actions, which include the establishment of an antiviral state, inhibition of cell proliferation, and modulation of the immune system, by binding to high-affinity cell surface receptors. Interferon-α, interferon-β, and interferon-ω, the so-called type I interferons, share a common receptor; interferon-γ binds to a quite distinct cell surface receptor.[4–7] The extent of the biological activity of IFN-α appears to be proportional to the number of type I receptors, as indicated by the sensitivity of human diploid fibroblasts containing one, two, or three copies of chromosome 21, which carries the gene(s) that code for the human interferon-α receptor.[8,9] The characteristic species specificity of the interferons is also determined at the level of the cell surface receptor.[1,10–12] Binding of interferon-α to its receptor is followed by the formation of an activated high-affinity IFN-receptor complex, which is a prerequisite for the subsequent development of both the antiviral and antiproliferative actions of interferon-α.[13–16] Binding of interferon-α to its receptor has been shown to result in the activation of the multimeric transcription factor ISGF3, its translocation to the nucleus, and activation of those genes that contain an interferon responsive element in their 5′-untranslated region, resulting in the establishment of the characteristic biologic actions of the interferon.[17–23]

A major component of the human type I interferon-receptor complex was recently cloned,[24] a transmembrane glycoprotein structurally related to the cytokine receptor superfamily and characterized by two tandem 200 amino acid domains, each consisting of two subdomains of equal size. The predicted folding of each of the 100 amino acid subdomains is consistent with the formation of the seven β strands (β1–7) of the immunoglobulin constant domain.[25,26] The use of IFN-α/βR% mice in

Laboratory of Viral Oncology, CNRS, 94801 Villejuif, France.

which the gene encoding this protein has been inactivated by homologous recombination has shown that this protein plays an important role in mediating the antiviral action of the type I interferons.[29] It is becoming clear, however, that this protein constitutes one of a number of proteins associated with the human type I interferon-receptor complex.[30,31]

The study of the IFN-receptor complex has heretofore been limited by the availability of sufficient quantities of purified functional receptor. The availability of recombinant soluble receptor, as well as two monoclonal antibodies that recognize different domains of this human type I interferon receptor protein, has allowed us to identify a region from amino acids 23 to 229 containing the epitopes recognized by the two anti-IFN receptor antibodies and containing a domain involved in ligand binding.

MATERIALS AND METHODS

Chemicals and reagents

All reagents for sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) were purchased from BioRad (South Richmond, CA). Horseradish peroxidase-conjugated sheep antimouse IgG and enhanced chemiluminescence kits (ECL) were purchased from Amersham (Little Chalfont, UK). Disulfosuccinimidyl tartrate and Iodobeads were purchased from Pierce.

Human recombinant interferon-α_2 was a gift from Dr. M. Fountoulakis (Biogen, Zurich, Switzerland), and interferon-α_8 was a gift from Dr. M. Grütter (Ciba-Geigy, Switzerland). They were iodinated as described[32] to a specific activity of 5×10^6 and 1.2×10^6 cpm/pmol, respectively.

Cell lines

Daudi, a human Burkitt's lymphoma-derived cell line[33]; Ly28, a human lymphoblastoid cell line[34]; and Madin Darby bovine kidney cells (MDBK) were maintained in RPMI 1640 medium (GIBCO, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum (FCS, or 15% FCS for Daudi cells), 2 mM L-glutamine, 100 U/ml of penicillin, and 100 μg/ml of streptomycin.

Monoclonal antibodies

The monoclonal antibodies 64G12 and 34F10 are mouse IgG_1 antibodies raised against recombinant proteins corresponding to the N-terminal region of the human IFN-α receptor truncated at residue 427 just before the transmembrane domain and expressed in COS cells and *E. coli*, respectively. The 64G12 antibody is a neutralizing antibody that inhibits both the binding of radiolabeled recombinant human α interferons to specific binding sites on the surface of human cells and the antiviral and antiproliferative actions of the type I interferons. The 34F10 antibody does not inhibit either the binding or biologic activities of any of the human type I interferons tested even though both antibodies exhibit similar affinities for the human IFN-α receptor (kD of 3–5 nM). The preparation and characterization of these antibodies have been described previously.[25]

SDS-PAGE and immunoblotting

SDS-PAGE was performed according to Laemmli.[36] After blotting of separated proteins onto a polyvinylidifluoride (PVDF) Millipore membrane, the membranes were saturated in 20 mM Tris, pH 7.6, 0.14 M NaCl, and 0.05% Tween 20 (TBS-T) containing 3% bovine serum albumin fraction V (Sigma) and washed three times with TBS-T. Immunoblots were performed by incubating membranes for 1 h at room temperature with TBS-T containing 1 μg/ml of affinity-purified MAb 64G12. The membranes were then washed three times with TBS-T and further incubated with horseradish peroxidase-conjugated sheep antimouse Ig (1:30,000 dilution) for 45 minutes. After a further five washes with TBS-T, the bands were visualized by ECL according to the manufacturer's specifications.

Immunoprecipitation of labeled cell surface proteins with monoclonal antibodies

Daudi cells (3×10^7) were surface labeled with ^{125}I using the Iodobead method according to the manufacturer's instructions. After labeling, the cells were washed with phosphate-buffered saline (PBS) and lysed for 30 minutes at 0°C with 50 mM Tris, pH 8, 0.5% Triton X-100, 240 mM NaCl, 10% glycerol, and 0.1 mM EDTA (ethylene diamine tetraacetic acid) containing 1 mM phenyl methyl sulfonyl fluoride, aprotinin, 10 μg/ml, leupeptin, and pepstatin, 2 μg/ml. Lysates were incubated for 2 h at 4°C with a mixture of affinity-purified mouse and rabbit IgG (20 μg each), followed by the addition of protein G-Sepharose (60 μl) for 4 h at 4°C. After centrifugation, the supernatants were incubated overnight with the antibodies indicated (15 μg) and then incubated with protein G-Sepharose (60 μl) for 4 h at 4°C. After five washes the samples were subjected to 10% SDS-PAGE under reducing conditions. Dried gels were exposed to x-ray film to detect labeled proteins.

Affinity cross-linking of [^{125}I]interferon-α_2 to its receptors

Daudi cells (1.5×10^6) in 12 ml RPMI 1640 and 10% FCS were incubated with 2600 U/ml (0.3 nM) of [^{125}I]interferon-α_2 for 2 h at 4°C. The cells were washed three times in PBS, resuspended in 12 ml PBS and 1 mM $MgCl_2$, cross-linked with 0.9 mM disulfosuccinimidyl tartrate (Pierce) for 15 minutes at 0°C, and lysed at a concentration of 0.75×10^6 cells/ml in the same Triton lysis buffer as before.

Immunoprecipitation with 34F10 and 64G12 MAbs was performed as described earlier.



FIG. 1. Western immunoblot analysis of the interferon-α/β receptor. Plasma membranes (75 μg) from Daudi cells: lane 1, Ly28 cells, lane 2; MDBK cells, lane 3, were prepared as described in Materials and Methods. Lane 4 shows the purified glycoprotein (0.1 μg) present in the supernatant of CHO cells transfected with a cDNA encoding the extracellular domain of the human interferon-α receptor protein. Samples were electrophoresed under reducing conditions on 10% SDS-polyacrylamide gels and electrotransferred onto nitrocellulose membranes (Amersham). Specific antigens to 64G12 MAb (1 μg/ml) were detected by enhanced chemiluminescence (ECL).



FIG. 2. The 64G12 and 34F10 MAbs recognize a major antigen of 105 and 110 kD, respectively. Another weak band of 76 kD is also recognized by both MAbs. Iodinated Daudi cells were lysed and precipitated using 15 μg of the MAb indicated. Preclearings were performed with mouse and rabbit IgG. Electrophoresis was run under reducing conditions on 10% SDS-polyacrylamide gels. Standard molecular weight protein markers are shown on the left.

RESULTS

Western blot analysis of the reactivity between MAb (64G12) and the native interferon-α receptor

Plasma membranes from the human Burkitt's lymphoma cell line Daudi, the human Epstein-Barr virus-transformed lymphoblastoid cell line Ly28, or the Madin Darby bovine kidney cell line MDBK,[27] and soluble interferon-α/β receptor were analyzed under reducing conditions by 10% SDS-PAGE[16] and electroblotted to PVDF. As shown in Fig. 1, the MAb 64G12 was found to recognize a 105 kD antigen on the surface of Daudi cells (lane 1) and a 115 kD antigen on the surface of Ly28 (lane 2). A 105 kD antigen was also detected in extracts of plasma membranes from both the human amniotic cell line WISH and the human promonocytic cell line U937 (data not shown). The antibody did not react with plasma membranes from heterologous MDBK cells (lane 3).

The antiinterferon-α receptor MAb was also found to recognize a 75 kD glycoprotein present in the supernatant of CHO (Chinese hamster ovary) cells transfected with a cDNA encoding the extracellular domain of a human interferon-α receptor protein (lane 4). All the bands detected by the MAb exhibited the characteristic diffuse form of glycoproteins. No cross-reactivity was detected when irrelevant antibodies were used as controls.

Receptor proteins detected by immunoprecipitation of surface-iodinated cells

To demonstrate the specificity of the 64G12 and 34F10 antibodies and to characterize the antigens recognized by these antibodies, Daudi cells were surface labeled with [^{125}I]iodine using Iodobeads according to the manufacturer's instructions. After iodination, cells were lysed and the immunoprecipitates obtained with both antibodies were analyzed by SDS-PAGE under reducing conditions (Fig. 2). The monoclonal antibody 34F10 precipitated a 110 kD band (lane 1), and the 64G12 MAb



FIG. 3. ^{125}I-IFN-α_2 was affinity cross-linked with disuccinimidyl tartarate to the cell surface receptors of Daudi cells. The lysates were immunoprecipitated with neutralizing anti-IFN receptor MAb 64G12 (lane 1) or nonneutralizing anti-IFN receptor MAb 34F10 (lane 2) and subjected to 10% SDS-PAGE under reducing conditions. Standard molecular weight protein markers are shown on the left.

precipitated a 105 kD band (lane 2), the apparent molecular weights of which correspond exactly to those determined by western blotting (see Fig. 1). An additional weak 76 kD band was detected by both antibodies upon immunoprecipitation of surface iodinated cells but not by western blotting (Fig. 1) or by immunoprecipitation of cross-linked [^{125}I]interferon-α_2–receptor complexes (Fig. 3).

Precipitation of cross-linked [^{125}I]interferon-α_2–receptor complexes by MAbs directed against an interferon-α receptor protein

[^{125}I]interferon-α_2–receptor complexes from Daudi cells were immunoprecipitated with the neutralizing MAb 64G12 (lane 1) or the nonneutralizing MAb 34F10 (lane 2). Protein G-Sepharose was added to recover immunoprecipitated complexes. SDS-PAGE analysis (Fig. 3) shows clearly that the MAb 64G12 (lane 1) cannot bind to the native receptor when interferon-α_2 is already bound to the receptor. In contrast, when the nonneutralizing MAb 34F10 is used, a labeled interferon-receptor complex with a mobility corresponding to 140 kD was readily detected (lane 2). The apparent molecular mass corresponds to that of the natural receptor together with that of [^{125}I]interferon-α_2 (20 kD). Both antibodies were unable to precipitate free [^{125}I]interferon-α_2, demonstrating that they recognize an epitope on the interferon-α receptor but not the interferon protein. Both MAbs were capable of recognizing the interferon-α receptor on Daudi cells when analyzed by flow cytometry.[28] Given that the MAb 64G12 is capable of inhibiting the binding of both interferon-α_2 and interferon-α_8 to Daudi cells; these results suggest that this monoclonal antibody recognizes a region of the native interferon receptor involved in ligand binding, which would explain why interferon-α_2 and MAb 64G12 are antagonistic in their action. We emphasize that this monoclonal antibody is able to recognize the same molecule to which labeled interferon binds in cross-linking experiments, strongly suggesting that the glycoprotein detected by the 64G12 MAb is indeed an interferon binding protein.

DISCUSSION

In this study we have identified a 105 kD (± 5 kD) antigen from the plasma membranes of both Daudi cells and Ly28 cells that is specifically recognized by two different monoclonal antibodies raised against a recombinant protein corresponding to the extracellular domain of one of the proteins that constitute the type I interferon receptor. The slight difference in mobility observed between the proteins detected on Daudi cells (105 kD) and Ly28 cells (115 kD) is probably a result of differences in posttranslational modifications of the IFN receptor in the two cell lines. It has been shown previously[26] that the primary sequence of the protein detected by the 64G12 MAb is the same in both Ly28 and Daudi cells. This led us to conclude that the differences seen by Western blotting are probably caused by differences in the glycosylation pattern of these proteins, as already shown for CD45.[26] In addition, it should be noted that the antigen detected on two other human cell lines (data not shown) is similar in size to that detected on Daudi cells (105 kD), and the higher apparent molecular weight observed on Ly28 cell line is an exception among the cell lines tested.

The 64G12 MAb is unable to recognize an epitope on heterologous bovine MDBK cells, which, although they bind human IFN-α, possess a quite distinct interferon receptor that nevertheless belongs to the same family of cytokine receptors (Fig. 1, lane 3). Furthermore, the 64G12 MAb does not recognize an epitope on mouse cells (data not shown), which do not bind human interferon and possess an interferon receptor with very little sequence homology with the human type I IFN receptor.[27,29] The bovine IFN-α receptor, however, retains its ability to bind labeled IFN-α following SDS-PAGE and transfer to an Immobilon PVDF membrane when sulfhydryl reducing agents and heating are omitted in sample preparation.[29,30] On the other hand, the 64G12 MAb prepared against the extracellular domain of the cloned IFN-α/β receptor protein produced in COS cells,[25] recognizes the extracellular region (75 kD) of the IFN-α/β receptor secreted by CHO cells transfected with the extracellular domain of the type I IFN receptor (Fig. 1, lane 4). To determine whether the two MAbs are able to recognize the

same antigen from ^{125}I-labeled cells, we immunoprecipitated labeled proteins after surface iodination of Daudi cells. Both monoclonal antibodies 64G12 and 34F10 were able to immunoprecipitate the same protein of 105 (± 5 kD). It should be noted that this molecular mass is in agreement with that observed by immunoblotting (Fig. 1).

Colamonici et al.[41,42] have described anti-IFN-α receptor monoclonal antibodies that recognize three proteins (110, 130, and 210 kD) in extracts of surface-labeled cells and in western blots, as well as after cross-linking of iodinated IFN-α_2 to the cell surface. The 110 kD protein described by Colamonici et al. (termed the α subunit) is similar in size to the major protein detected by both the 64G12 and 34F10 antibodies. Further experiments are necessary, however, to demonstrate whether these are indeed the same protein. In addition to the major antigen (105 kD) detected, another weak, 76 kD band (Fig. 2) was also recognized specifically by both MAbs. We do not know, however, whether this band is an interferon binding protein. The presence of such a band raises the question of the requirement of an accessory protein for a functional interferon receptor system.[1,8,30,38,43] Novick et al.[21] recently described an additional IFN binding protein that appears to be part of the human type I IFN receptor complex. In addition to determining the identity of this 76 kD antigen, we are currently investigating the question of why the 76 kD band is not detected by ligand blotting with IFN-α_2 or IFN-α_8 or by immunoblotting with the two monoclonal MAbs 64G10 and 34F10. The slight differences observed in the migration of the proteins detected by the two antibodies (Fig. 2) could be related to differences in the epitope recognized by the two antibodies. The 34F10 antibody was raised against nonglycosylated, *Escherichia coli*-derived, soluble IFN-α receptor protein and could therefore recognize an epitope near a glycosylation site that is not always glycosylated. The antibody 64G12 was raised against glycosylated, COS cell-derived, soluble IFN-α receptor and may consequently recognize and immunoprecipitate a more glycosylated form of the receptor. It is of considerable interest that labeled IFN cross-linked to the cell surface receptor on Daudi cells could be immunoprecipitated with the nonneutralizing MAb 34F10 but not with neutralizing MAb 64G12. The interferon-receptor complex of 140 kD that was identified is in good agreement with the mobility of a major cross-linked complex described previously.[44–47] The fact that no interferon-receptor complex is immunoprecipitated with the neutralizing MAb 64G12 indicates that the ligand (IFN) and the antagonist (MAb 64G12) are competing for a common site on the extracellular domain of this interferon receptor binding protein. Both antigens from Daudi or Ly28 cells are IFN-α binding proteins: they could be specifically cross-linked by ^{125}I-IFN-α_2 and then immunoprecipitated with the nonneutralizing MAb 34F10 but not with the antagonist-neutralizing MAb 64G12. Thus, we have shown by these experiments that a component of the ligand binding site of the human interferon-α receptor is localized at least partly within the first half of the molecule (amino acids 23–229), determined by the ability of the MAbs to recognize recombinant proteins corresponding to truncated fragments of the extracellular domain of the IFN receptor protein (D. Magnuse and I. Plavec, unpublished results). Work is in progress using overlapping synthetic peptides to delineate further the precise position of the epitopes recognized by both antibodies. The region recognized by both monoclonal antibodies corresponds to the first of the two repeated domains, which are homologous to the type II interferon receptor.[26–28,48,49] The results of our experiments, however, do not exclude the possibility that the membrane-proximal (second) domain is not involved in ligand binding.

In conclusion, in this study we have delineated (by the use of two monoclonal antibodies) a component of the ligand binding site on the extracellular domain of an interferon-α/β receptor protein. Determination of the precise organization of this ligand binding domain, however, must await crystallization of the purified soluble interferon binding protein, alone or complexed with interferon, and subsequent x-ray diffraction studies.

ACKNOWLEDGMENTS

We are indebted to Dr. Ian Gresser for his constant support and advice. This work was supported in part by grants from the Laboratoire Européen de Biotechnologie SA, the Association pour la Recherche sur le Cancer, the DRET (Contract No. 91-192), and the Fondation pour la Recherche Médicale.

REFERENCES

1. PETSKA, S., LANGER, J.A., ZOON, K.C., and SAMUEL, C.E. (1987). Interferons and their actions. *Annu. Rev. Biochem.* *56*, 727–777.
2. PFEFFER, L.M. (ed.) (1987). *Mechanisms of Interferon Action*, Boca Raton, FL: CRC Press.
3. DE MAEYER, E., and DE MAEYER-GUIGNARD, J. (1988). *Interferons and other regulatory cytokines*, New York: Wiley Interscience.
4. AGUET, M. (1980). High-affinity binding of ^{125}I-labelled mouse interferon to a specific cell surface receptor. *Nature* *284*, 459–461.
5. BRANCA, A.A., and BACIGLONI, C. (1981). Evidence that types I and II interferons have different receptors. *Nature* *294*, 768–770.
6. MERLIN, G., FALCOFF, E., and AGUET, M. (1985). ^{125}I-labeled human interferons alpha, beta and gamma: comparative receptor binding data. *J. Gen. Virol.* *66*, 1149–1152.
7. MOGENSEN, K.E., UZÉ., G., and EID, P. (1989). The cellular receptor for the alpha-beta interferons. *Experientia* *45*, 500–508.
8. TAN, Y.H. (1976). Chromosome 21 and the cell growth inhibitory effect of human interferon preparations. *Nature* *260*, 141–143.
9. YAP, W.H., TEO, T.S., and TAN, Y.H. (1986). An early event in the interferon-induced transmembrane signaling process. *Science* *234*, 355–358.
10. ZOON, K.C., and ARNHEITER, H. (1984). Studies of the interferon receptors. *Pharmacol. Ther.* *24*, 259–278.
11. JUNG, V., RASHIDBAIGI, A., JONES, C., TISCHFIELD, J.A., SHOWS, T.B., and PESTKA, S. (1987). Human chromosome 6 and 21 are required for sensitivity to human interferon gamma. *Proc.Natl. Acad. Sci. USA* *84*, 4151–4155.
12. GIBBS, V.C., WILLIAMS, S.R., GRAY, P.W., SCHREIBER, R.D., PENNICA, D., RICE, G., and GOEDDEL, D.V. (1991). The extracellular domain of the human interferon gamma receptor interacts with a species-specific signal transducer. *Mol. Cell Biol.* *11*, 5860–5866.

13. HEMMI, S., MERLIN, G., and AGUET, M. (1992). Functional characterization of a hybrid human-mouse interferon γ receptor: evidence for species-specific interaction of the extracellular receptor domain with a putative signal transducer. Proc. Natl. Acad. Sci. USA 89, 2737–2741.
14. MOGENSEN, K.E., and BANDU, M.-T. (1983). Kinetic evidence for an activation step following the binding of human interferon α_2 to the membrane receptors of Daudi cells. Eur. J. Biochem. 134, 355–364.
15. ZOON, C., ARNHEITER, H., and FITZGERALDS, D.J.P. (1986). Procedures for measuring receptor-mediated binding and internalization of human interferon. Methods Enzymol. 119, 332–339.
16. PFEFFER, L.M., STEBBING, N., and DONNER, D.B. (1987). Cytoskeletal association of human α-interferon-receptor complexes in interferon-sensitive and resistant lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 84, 3249–3253.
17. FRIEDMAN, R.L., and STARK, G.R. (1985). α-interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 314, 637–639.
18. REICH, N.C., EVANS, B., LEVY, D.E., FAHEY, D., KNIGHT, E., and DARNELL, J.E., Jr. (1987). Interferon-induced transcription of a gene encoding a 15 kD protein depends on an upstream enhancer element. Proc. Natl. Acad. Sci. USA 84, 6394–6398.
19. COHEN, B., PEREZ, D., VAIMAN, D., BENECH, P., and CHEBATH, J. (1988). Enhancer-like interferon responsive sequences of the human and murine (2'-5') oligoadenylate synthetase gene promoters. EMBO J. 7, 1411–1419.
20. KESSLER, D.S., LEVY, D.E., and DARNELL, J.E., Jr. (1988). Two interferon-induced nuclear factors bind a single promoter element in interferon-stimulated genes. Proc. Natl. Acad. Sci. USA 85, 8521–8525.
21. PORTER, A.C.G., CHERNAJOVSKY, Y., DALE, T.C., GILBERT, C.S., STARK, G.R., and KERR, I.M. (1988). Interferon response element of the human gene 6-16. EMBO J. 7, 85–92.
22. RUTHERFORD, M.N., HANNIGAN, G.E., and WILLIAMS, B.R.G. (1988). Interferon-induced binding of nuclear factors to promoter elements of the 2-5A synthetase gene. EMBO J. 7, 751–759.
23. DALE, T.C., ROSEN, J.M., QUILLE, M.J., LEWIN, A.R., PORTER, A.G.C., KERR, I.M., and STARK, G.R. (1989). Overlapping sites for constitutive and induced DNA binding factors involved in interferon-stimulated transcription. EMBO J. 8, 831–839.
24. LEVY, D.E., KESSLER, D.S., PINE, R.E., REICH, N., and DARNELL, J.E., Jr. (1988). Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev. 2, 383–393.
25. FU, X.Y., KESSLER, D., VEALS, S.A., LEVY, D.E., and DARNELL, J.E., Jr. (1990). ISGF-3, the transcriptional activator induced by interferon α, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. USA 87, 8555–8559.
26. UZÉ, G., LUTFALLA, G., and GRESSER, I. (1990). Genetic transfer of a human interferon-α receptor into mouse cells: cloning and expression of its cDNA. Cell 60, 225–234.
27. UZÉ, G., LUTFALLA, G., BANDU, M.-T., PROUDHON, D., and MOGENSEN, K.E. (1992). Behavior of a cloned murine interferon α/β receptor expressed in homospecific or heterospecific background. Proc. Natl. Acad. Sci. USA 89, 4774–4778.
28. MOUCHEL-VIELH, S., LUTFALLA, G., MOGENSEN, K.E., and UZÉ, G. (1992). Specific antiviral activities of the human α interferons are determined at the level of receptor (IFNAR) structure. FEBS Lett. 313, 255–259.
29. MÜLLER, U., STEINHOFF, U., REIS, L.F.L., HEMMI, S., PAVLOVIC, J., ZINKERNAGEL, R., and AGUET, M. (1994). Functional role of type I and type II interferons in antiviral defense. Science 264, 1918–1921.
30. COLAMONICI, O.R., and DOMANSKI, P. (1993). Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21. J. Biol. Chem. 268, 10395–10399.
31. NOVICK, D., COHEN, B., and RUBINSTEIN, M. (1994). The human interferon α/β receptor: characterization and molecular cloning. Cell 77, 391–400.
32. MOGENSEN, K.E., and UZÉ, G. (1986). Radioiodination of human alpha interferons by the chloramine T method. Methods Enzymol. 119, 267–276.
33. KLEIN, E., KLEIN, G., NADKARNI, J.S., NADKARNI, J.J., WIGZELL, H., and CLIFFORD, K. (1968). Surface IgM-kappa specificity on a Burkitt's lymphoma cell in vivo and in derived lines. Cancer Res. 228, 1300–1306.
34. KLEIN, G., DOMBOS, L., and GOTHOSKAR, B. (1972). Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB virus. Int. J. Cancer 10, 44–49.
35. BENOIT, P., MAGUIRE, D., PLAVEC, I., KOCHER, H., TOVEY, M.G., and MEYER, F. (1993). A monoclonal antibody to recombinant human IFN-α receptor inhibits biologic activity of several species of human IFN-α, IFN-β, and IFN-ω. J. Immunol. 150, 707–716.
36. LAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.) 227, 680–685.
37. UZÉ, G., BANDU, M-T., EID, P., GRÜTTER, M., and MOGENSEN, K.E. (1988). Electrostatic interactions in the cellular dynamics of the interferon-receptor complex. Eur. J. Biochem. 171, 683–691.
38. LAL, R., VISSER, L., and POPPEMA, S. (1991). Tissue distribution of restricted common antigens: a comprehensive study with protein- and carbohydrate-specific CD45R. Lab. Invest. 64, 844–848.
39. SCHWABE, M., PRINCLER, G.L., and FALTYNEK, C.R. (1988). Characterization of the human type I interferon receptor by ligand blotting. Eur. J. Immunol. 18, 2009–2014.
40. PUVANAKRISHNAN, R., and LANGER, J.A. (1990). Detection and analysis of interferon-α receptors on plasma membranes and in detergent extracts. J. Interferon Res., 10, 299–307.
41. COLAMONICI, O.R., D'ALESSANDRO, F., DIAZ, M.O., GREGORY, S.A., NECKERS, L.M., and NORDAN, R. (1990). Characterization of three monoclonal antibodies that recognize the interferon α_2 receptor. Proc. Natl. Acad. Sci. USA 87, 7230–7234.
42. COLAMONICI, O.R., PFEFFER, L.M., D'ALESSANDRO, F., PLATANIAS, L.C., GREGORY, S.A., ROSOLEN, A., NORDAN, R., CRUCIANI, R.A., and DIAZ, M.O. (1992). Multichain structure of the IFN-α receptor on hematopoietic cells. J. Immunol. 148, 2126–2132.
43. HU, R., GAN, Y., LIU, J., MILLER, D., and ZOON, K.C. (1993). Evidence for multiple binding sites for several components of human of human lymphoblastoid interferon-α. J. Biol. Chem. 268, 12591–12595.
44. JOSHI, A.R., SARKAR, F.H., and GUPTA, S.L. (1983). Interferon receptors. Cross-linking of human leukocyte interferon α-2 to its receptor on human cells. J. Biol. Chem. 257, 13884–13887.
45. FALTYNEK, C.R., BRANCA, A.A., McCANDLESS, S., and BACILIONI, C. (1983). Characterization of an interferon receptor on human lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 80, 3269–3273.